A Study of BMS-986205 Given in Combination With Nivolumab in Patients With Advanced Tumors

Sponsor
Bristol-Myers Squibb
Study ID
NCT03192943
Phase
PHASE1
Status
Completed

Conditions

  • Advanced Cancer

Eligibility Criteria

Sex
ALL
Age
20 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • BMS-986205 — DRUG
    Specified dose on specified days
  • Nivolumab — BIOLOGICAL
    Specified dose on specified day

Study Details

The purpose of this study is to assess the safety and tolerability for the combination therapy of BMS-986205 and Nivolumab in patients with advanced tumors

Key Dates

Start date
Jun 23, 2017
Status verified
Mar 2019
Primary completion
Dec 11, 2018
Completion
Dec 11, 2018

Study Design

Enrollment
11 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Dose Escalation
    monotherapy and combination therapy

Primary Outcome Measure

Incidence of Adverse Events (AEs) [ Time Frame: 15 months ]

Related Studies